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Summary
Background Atopic dermatitis (AD) is a chronic allergic inﬂammatory disease, which manifests
itself with eczematous skin lesions.
Objective We compared the clinical efﬁcacy of tacrolimus ointment (0.1%) given twice a day and
oral cyclosporine (3mg/kg) given once daily. Rescue medication for itching included cetirizine
10–20mg (equal to one or two tables).
Methods Thirty patients, aged 13–45 years (mean  SD 27.1  10.9), with a history of moderate-
to-severe AD were randomized to treatments, 15 patients for each treatments. Assessment of efﬁcacy
was based on SCORAD, on scores of daily itching, erythema, interference with sleep, due to the skin
condition and days without use of cetirizine tablets. SCORAD, measured on a scale (0–103), was
evaluated before treatment (0) and at 7, 14, 21, 28, 35 and 42 days after treatment. Similarly, the
means of daily symptoms, on a scale (0–3), were evaluated before the treatment (0) and at 7, 14, 21,
28, 35 and 42 days after treatment; ﬁnally, on day without use of cetirizine tablets. The safety of the
study treatments was assessed through haematologic, biochemical and urinary testing and on systolic
and diastolic blood pressures and heart rate measurements.
Results SCORAD decreased in the two treatment groups 14 days after the beginning of the period
study. However, the patients in tacrolimus ointment group reported signiﬁcantly lower SCORAD
than those treated with oral cyclosporine. Overall SCORAD, as assessed by the area under the curve
(AUC) day0–42 (score/day), was signiﬁcantly lower in the tacrolimus ointment group when compared
with oral cyclosporine (Po0.001). Similarly, AUC day0–42 (score/day) for itching, erythema and
number of nights without interference with the sleep due to skin condition were signiﬁcantly lower in
the group of patients treated with tacrolimus compared with those treated with cyclosporine
(P5 0.003, 0.005 and 0.01, respectively). As regards the use of rescue medication, expressed by
median of number of days without use of anti-H1, it was signiﬁcantly lower in the group treated with
tacrolimus (82.5) than in the cyclosporine group (76.5) (P5 0.03). There were no appreciable changes
in haematological and biochemical indices, in both treatments groups.
Conclusion The results of this comparative study demonstrate that tacrolimus ointment twice daily
and cyclosporine administered orally once daily are effective on SCORAD, daily symptoms and anti-
H1 rescue. When we compared tacrolimus and cyclosporine there was a faster onset of action in the
group treated with tacrolimus. The two drugs presented the same safety. However, these data
support the preferential use of topical tacrolimus 0.1% in AD, because cyclosporine has potential
side-effects.
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Introduction
Atopic dermatitis (AD) is a chronic allergic inﬂammatory
disease, which manifests itself with eczematous skin lesions
[1]. Recently, an increasing number of patients, particularly
adults, had serious problems, with only partial improvement
or even worsening of lesions, due to resistance to topical
steroid therapy. Precise mechanisms underlying AD remain
unclear. A biphasic immunological pattern has been sug-
gested, starting with a Th2-type allergic reaction, being
allergen-speciﬁc, followed by a Th1-type allergic reaction,
non-allergen speciﬁc. The Th2-type reaction is important in
induction of inﬂammation, whereas Th1-type reaction is
responsible for maintenance and aggravation of the inﬂam-
mation, representing the chronic phase of AD [2, 3, 7].
In the majority of cases, in babies, AD ends with a phase of
prolonged remission [8]. Cutaneous signs on the hands persist
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during adulthood in 60% of the cases, with serious subtype of
disease. AD continues in adulthood in the 80% of patients
with aggravating factors, such as family history of AD,
female subject, an early occurrence of the illness, generalized
symptoms in childhood and association with asthma and
allergic rhinitis. The persistence of AD in adulthood is only
15% in absence of these factors [9]. A recent review points out
the new insights in physiopathology. The author suggests that
the release of mediators (from mast cells, basophils and
eosinophils) and of cytokines can be responsible for the
thickening and dryness of the skin [9].
However, drugs that suppress both types of allergic
reactions would thus be useful for the treatment of AD. Of
variable efﬁciency, systemic corticotherapy is contra-indi-
cated because of the systemic side-effects of a long-term
treatment, the rebound phenomenon upon cessation of the
treatment and the risk of adrenal insufﬁciency [8, 9]. There is
a controversy concerning the use of antihistamines anti-H1, in
AD. However, their usefulness against cutaneous itching and
their anti-inﬂammatory properties remain to be established
[9–11].
Cyclosporine and tacrolimus, two potent immunosuppres-
sants, with similar mechanisms of action, have an effect on
the T immune response by blocking the activation of T cells
and the antigen presentation by Langerhans cells. Moreover,
they inhibit the histamine liberation by the mast cells and the
basophils [9–12]. Both cyclosporine and tacrolimus have been
used in the treatment of AD [9, 13–15].
No studies had compared tacrolimus administered topically
and cyclosporine administered orally in adult patients
affected by AD. This study was designed to evaluate the
efﬁcacy and the safety of 0.1% tacrolimus ointment applied
to up to 50% of the total body surface area of adults twice
daily and cyclosporine (3mg/kg) administered orally once
daily, in patients affected by moderate-to-severe AD.
Materials and methods
Patients
The patients were selected by ﬁle of Dipartimento di
Medicina Clinica Esperimentale of Verona, Section of
Internal Medicine, based on their clinical history of AD
and with a conﬁrmed diagnosis of moderate-to-severe AD,
according to the criteria of Rajka and Langeland [16]. All
patients have been treated with topical corticosteroids and
showed partial improvement to the treatment. A total of 30
patients (nine males and 21 females), age ranging from 13 to
45 years, were enrolled. The main exclusion criteria were
treatment with systemic corticosteroids, cytotoxic agents or
phototherapy within 6 weeks prior to entry, previous
treatment with tacrolimus or with cyclosporine, abnormal
renal or liver function, hyper-tension and, ﬁnally, pregnancy
or breastfeeding.
A randomized, double-blind, double dummy, placebo-
controlled, parallel-group study was designed. Patients
underwent the following treatments:
1. Oral cyclosporine tablets (3mg/kg) given once a day and
placebo of tacrolimus (ointment without the drug, see
below) given twice a day;
2. 0.1% tacrolimus ointment given twice a day and placebo
of cyclosporine.
Rescue medication for itching included cetirizine 10mg
(Zirtecs, Torino, Piemonte, Italy). The patients could take
from one to two tablets of cetirizine a day, as rescue. No other
medication was permitted during the trial.
The pharmacist of the University Hospital of Verona
prepared for each patient a speciﬁc set of tablets to be used
for the study, containing either commercially available tablets
of cyclosporine (Sandimmun neorals, Novartis Pharma,
Italy) or tablets of placebo. To prepare the 0.1% ointment,
the content of tacrolimus capsules (total 100mg) was mixed
with 100 g of hydrophilic petrolatum (white petrolatum
composed of 8% bleached beeswax, 3% stearyl alcohol and
3% cholesterol). The placebo ointment of tacrolimus was
only made of 100 g of hydrophilic petrolatum without
tacrolimus [17]. All treatments were administered by a person
unaware who was participating in the study.
Patients were treated for 42 days after 7 days of run-in. All
patients started during the same month. All patients enrolled
in the study were sensitized to house dust mites allergens. The
patients attended the clinic every 7 days after beginning of
treatment and 14 days after ending of the treatment period.
At each visit, SCORAD was assessed and the patients
received a daily record diary for AD symptoms (see below).
The local ethics committee of the hospital (Verona, Italy)
approved the protocol and patients gave informed written
consent to participate in the study.
Severity of the dermatitis was evaluated according to
SCORAD [18]. Brieﬂy, for computation of the SCORAD
value the percentage of involved body surface is recorded.
Regional body surface area tabulation was used to assess the
severity of dermatitis over four body areas: head and neck
(H), upper extremities (U), trunk (T) and lower extremities
(L) were assigned proportionate body surface areas of 10%
(H), 20% (U), 30% (T) and 40% (L), roughly consistent with
the ‘rule of nines’. Six intensity items (erythema, edema/
papulation, oozing/crusts, excoriations, licheniﬁcation and
dryness) were then evaluated, ranging 0–3 (absent to severe)
and the patients indicate the severity of pruritus and sleep loss
(0–10). Total score was thus calculated using the following
equation: SCORAD5 (0.2  area)1(3.5  [eritema1edema/
papulation1oozing/crusts1excoriations1licheniﬁcation 1
dry skin])1subjective score. Index scores of disease severity
ranged from 0 to 103.
Assessment of symptoms
Patients were instructed to register their daily symptoms on a
diary card. AD symptoms included itch intensity, erythema
and interference with sleep due to the skin condition. Itch
intensity was scored as follows: 0, no itch; 1, mild itch; 2,
moderate itch; and 3, severe itch. Area of erythema was
scored as follows: 0, no erythema; 1, mild erythema; 2,
moderate erythema; and 3, severe erythema. Similarly, the
patients reported the interference with sleep due to their skin
condition on a scale from 0 to 3: 0, none; 1, mild; 2, moderate;
and 3, severe.
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Fourteen days after the double-blind treatment period, the
patients were evaluated by SCORAD and by their sponta-
neous recording.
Laboratory data
Blood samples were withdrawn from each patients every 7
days to assess haematologic (haemoglobin, red blood cells,
platelets and white blood cells) and biochemical (serum
electrolytes [sodium and potassium], renal [creatinine, urea
and urinary analysis], hepatic function [alkaline phosphatase,
AST, ALT and GGT] and glucose-fasting) testing.
Serum total and speciﬁc IgE and blood eosinophil counts
were performed after the run-in period and at the end of the
period study (after 42 days).
Safety and adverse events
The safety of the study treatments was assessed through
haematologic, biochemical and urinary testing. Systolic and
diastolic blood pressures and heart rate were recorded at each
visit for each patient. Adverse events were recorded, at each
clinic visit, through the spontaneous reports by the patients
and through a speciﬁc interview or by direct observation of
the investigators. The investigator rated the severity of the
adverse events using a three-point scale (mild, moderate or
severe) and the relationship of each adverse event using the
categories unrelated, unlikely, possible, probable and almost
certain.
Statistical analysis
The values of SCORAD and daily symptoms (itching and
erythema during the day, interference with sleep due to the
skin condition and cetirizine use), after the run-in period,
were used to establish baseline values. The same parameters
were evaluated at 7, 14, 21, 28, 35 and 42 days after the period
study. The serial SCORAD of the 42 days study period were
compiled into a graph of disease severity (out to 103) vs. time
(days). The area under the curve (AUC) was calculated using
the trapezoidal method and denoted as AUC0–42. Such, the
measure gives an overall assessment of each patient’s
SCORAD throughout the 42-day investigation period [19].
Similarly we examined the daily symptoms, recorded on the
diary card, using the weekly means. Data were examined
using unpaired Student’s test. The Kruskal–Wallis test
logarithmic transformation was performed on skewed vari-
ables such as IgE levels and eosinophils. Finally, the use of
rescue medication was expressed as the median of days
without use of anti-H1. Data of SCORAD and of symptoms
were reported as mean ( standard error of the mean) and as
mean difference (95% conﬁdence interval) between the means
of the individual scores of the treatments, recorded every 7
days. A value of Po0.05 was considered signiﬁcant.
Results
All the patients concluded the entire study, including the
follow-up period. The baseline characteristics of the patients
were reported in Table 1. There were no signiﬁcant differences
between any variable.
SCORAD
SCORAD was evaluated every 7 days and each time point is
illustrated in Fig. 1 and in Table 2. SCORAD decreased in the
two treatment groups 14 days after the beginning of the
period study. However, the patients in the tacrolimus
ointment group reported signiﬁcantly lower SCORAD than
those treated with oral cyclosporine. The difference (mean,
95% CI) between the means of the individual scores of the
Table 1. Patients characteristics
Tacrolimus Cyclosporine P
Nw patients 15 15
M/F ratio 5/10 4/11 NS
Age years  SD 27.1  10.9 26.6  10.4 NS
Height (cm)  SD 160  8.2 165  7.1 NS
Weight (kg)  SD 58.5  6.3 56.4  5.8 NS
Median time since diagnosis
of AD (years) 19 15 NS
Body surface area  SD 66.0  13.5 71.0  13.7 NS
Head and neck (%)* 100 100 NS
Upper extremities (%)* 90 70 NS
Trunk (%)* 60 50 NS
Lower extremities (%)* 50 80 NS
SCORAD (mean  SEM) 69.0  3.9 73.7  3.5 NS
Atopy (%) 100 100 NS
Sensitization to pollen (%)w 0 0 NS
Sensitization to indoor
allergens (%)w 100 100 NS
Asthma (%)w 100 100 NS
Rhinitis (%)w 100 100 NS
Conjunctivitis (%)w 100 100 NS
Serum total IgE (kU/L) 1603.1 3232.4 NS
Blood eosinophil counts
( 103 mL) 0.18 0.16 NS















Fig. 1. Graph to show mean (SEM) SCORAD (out to 103) vs. time (days)
for patients after treatment with tacrolimus ointment (0.1%) and oral
cyclosporine (3 mg/kg).
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treatments, recorded every 7 days, was: after 14 days,  12.6
( 18.7 to  6.4); after 21 days,  11.6 ( 17.7 to  5.4);
after 28 days,  18.7 ( 4.8 to  12.5); and after 35 days,
 10.1 ( 16.2 to  3.9). By contrast, after 42 days the
mean of SCORAD was not signiﬁcantly different:  1.3
( 7.4 to 4.8). Overall SCORAD, as assessed by the AUC0–42,
was signiﬁcantly lower in the tacrolimus ointment group
when compared with oral cyclosporine (Po0.001). At the
follow-up visit, no changes were detected.
Daily symptoms
Similarly, AUC0–42 for itching, erythema and number of
nights without interference with the sleep due to skin
condition were signiﬁcantly lower in the group of patients
treated with tacrolimus compared with those treated with
cyclosporine (P5 0.003, 0.005 and 0.01, respectively) (Figs
2a–c, Table 3).
Use of rescue medication
Regarding the use of rescue medication, expressed by median
of the number of days without use of anti-H1, it was
signiﬁcantly lower in the group treated with tacrolimus (82.5)
than in the cyclosporine group (76.5) (P5 0.03).
Serum total IgE and blood eosinophil counts
Serum total IgE and blood eosinophil counts after the period
treatment, both in tacrolimus group and in cyclosporine
group, presented a reduction. As regards serum total IgE, the
geometric means in cyclosporine group were 1603.1 kU/L
before treatment and 1069.2 kU/L after treatment (P5 0.7).
In the tacrolimus group, the geometric means were
3232.4 kU/L before treatment and 2399.1 kU/L after treat-
ment (P5 0.6). No difference was found between the two
groups before (P5 0.8) and after treatment (P5 0.7). As
regards blood eosinophil counts, the geometric means in
cyclosporine group were 0.18  10 3mL before treatment
and 0.08  10 3mL after treatment (P5 0.04). In tacrolimus
group, the geometric means were 0.16  10 3mL before
treatment and 0.09  10 3mL after treatment (P5 0.06). No
differences were found between the two groups before








































Fig. 2. (a–c) Graphs to show means (SEM) itching, erythema and number
of nights without interference with the sleep due to skin condition (out to 3)
vs. time (days) for patients after treatment with tacrolimus ointment (0.1%)
and oral cyclosporine (3 mg/kg).
Table 2. Summary of SCORAD (out to 103) recording during the investigation period
SCORAD (out of 103) Tacrolimus Cyclosporine Mean difference 95% CI P-value
After run-in* 69.0 (3.9) 73.7 (3.5) 4.7 (10.8 to 1.4) 0.1
7 days after treatment* 63.8 (2.4) 68.7 (2.2) 4.9 (11.0 to 1.2) 0.1
14 days after treatment* 54.7 (2.3) 67.3 (2.3) 12.6 (18.7 to  6.4) o0.001
21 days after treatment* 44.3 (0.2) 55.9 (3.7) 11.6 (17.7 to  5.4) o0.001
28 days after treatment* 24.8 (1.1) 43.5 (0.4) 18.7 (24.8 to 12.5) 0.001
35 days after treatment* 11.4 (0.6) 21.5 (1.58) 10.1 (16.2 to 3.9) 0.001
42 days after treatment* 7.3 (0.7) 8.6 (0.54) 1.3 (7.4 to 4.8) 0.6
Overall SCORAD–AUC0–42 (score/days) 2052.2 (69.0) 1660.0 (110.2) 392.2 (554.7 to  229.6) o0.001
*Expressed as mean  SEM.
642 M. L. Pacor et al.
r 2004 Blackwell Publishing Ltd, Clinical and Experimental Allergy, 34:639–645
Safety and adverse events
There were no appreciable changes in the haematological and
biochemical indices. Serum creatinine was higher in the group
treated with cyclosporine after the period of the study, but all
values were below the upper limit of normal (0.8–1.6mg/dL).
No clinically signiﬁcant changes were noted, for either
treatment, in systolic and diastolic blood pressures and heart
rate. During the 6-week treatment period, the number of
patients reporting adverse events was equal in the two
treatment groups (four in the cyclosporine A group and four
in the tacrolimus group, respectively). The events characterized
by the investigator were mild. The patients in the tacrolimus
group reported the sensation of skin burning and the
patients in the cyclosporine A group gastric irritation (one
patient) and headache (three patients). During the follow-
up period, no AD exacerbation was observed in the two
groups.
Discussion
AD is a chronic, relapsing, highly pruritic, inﬂammatory skin
disease. Eczema is a chronic inﬂammation of the skin with a
majority of activated T lymphocytes. Controlling eczema
leads to relief not only of the skin inﬂammation but also of
itching.
Schematically, the therapeutical approach required for a
successful treatment include: (i) identiﬁcation and avoidance
of the immunologic trigger factors (i.e. allergens, infections,
irritants, psychogenic factor); (ii) reduction of the inﬂamma-
tory cell inﬁltration in the dermis; and (iii) blockade of the
effect of the cytokines and mediators released by the
inﬂammatory cells [9].
As for the available pharmacological options for AD, these
are directed at hydrating the skin, reducing inﬂammation,
and relieving symptoms such as pruritus and sleep distur-
bance. Depending on its severity, AD is usually managed with
the liberal use of emollients, topical corticosteroids, anti-
histamines and antibiotics [20].
Table 3. Summary of efficacy parameters recording during the investigation period: itching, erythema and interference with sleep due to skin condition
Tacrolimus Cyclosporine Mean difference 95% CI P-value
Itching (out of 3)
After run-in* 2.41 (0.08) 2.58 (0.07) 0.17 (0.42 to 0.08) 0.1
7 days after treatment* 1.77 (0.10) 2.42 (0.09) 0.65 (0.91 to  0.40) o0.001
14 days after treatment* 1.51 (0.11) 1.98 (0.09) 0.47 (0.72 to  0.21) o0.001
21 days after treatment* 1.07 (0.10) 1.41 (0.11) 0.12 (0.59 to  0.09) 0.008
28 days after treatment* 0.88 (0.10) 1.07 (0.09) 0.12 (0.43 to 0.06) 0.1
35 days after treatment* 0.40 (0.06) 0.55 (0.07) 0.15 (0.41 to 0.09) 0.1
42 days after treatment* 0.35 (0.05) 0.48 (0.06) 0.12 (0.67 to 0.17) 0.1
Overall itching–AUC42 (score/days) 42.9 (2.92) 56.6 (2.87) 13.7 (22.3 to  5.07) 0.003
Erythema (out of 3)
After run-in* 2.37 (0.07) 2.54 (0.07) 0.17 (0.42 to 0.07) 0.1
7 days after treatment* 1.71 (0.09) 2.11 (0.07) 0.40 (0.64 to  0.15) 0.002
14 days after treatment* 1.51 (0.11) 1.98 (0.09) 0.47 (0.72 to  0.22) o0.001
21 days after treatment* 1.08 (0.10) 1.44 (0.11) 0.35 (0.60 to  0.10) 0.008
28 days after treatment* 0.89 (0.10) 1.07 (0.09) 0.18 (0.43 to 0.06) 0.1
35 days after treatment* 0.41 (0.06) 0.60 (0.08) 0.18 (0.43 to 0.06) 0.1
42 days after treatment* 0.36 (0.06) 0.49 (0.06) 0.12 (0.37 to 0.12) 0.1
Overall itching–AUC0–42 (score/days) 42.6 (3.00) 54.8 (2.34) 12.2 (20.2 to  4.16) 0.005
Interference with sleep due to skin condition (out of 3)
After run-in* 2.08 (0.09) 2.10 (0.08) 0.01 (0.26 to 0.23) 0.9
7 days after treatment* 1.71 (0.09) 2.11 (0.07) 0.40 (0.65 to  0.14) 0.002
14 days after treatment* 1.45 (0.11) 1.60 (0.10) 0.14 (0.39 to 0.11) 0.2
21 days after treatment* 1.09 (0.10) 1.44 (0.11) 0.35 (0.61 to  0.10) 0.006
28 days after treatment* 0.91 (0.10) 1.12 (0.09) 0.21 (0.46 to 0.03) 0.09
35 days after treatment* 0.41 (0.06) 0.60 (0.07) 0.18 (0.43 to 0.06) 0.1
42 days after treatment* 0.35 (0.05) 0.50 (0.06) 0.14 (0.43 to 0.1) 0.1
Overall interference with sleep–AUC0–42 (score/days) 42.2 (3.17) 52.4 (2.37) 10.1 (18.4 to  1.81) 0.01
*Expressed as mean  SEM.
Table 4. Geometric means of serum total IgE (kU/L) and blood eosinophil
counts ( 103 mL) obtained in the two treatment groups
Serum total IgE (kU/L)
Blood eosinophil









Cyclosporine 1603.1 1069.2 0.18* 0.08
Tacrolimus 3232.4 2399.1 0.16 0.09
No differences between the groups before and after period of treatment.
*Comparing blood eosinophil counts in the cyclosporine group before and after
treatment period, P5 0.04.
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For patients with a long history of disease, an extensive
body surface area involvement, or the presence of facial
lesions, the therapeutical options are more limited. In such
cases, the use of mild-to-high potency topical steroids are not
recommended for long-term use or use on the skin face, neck
and intertriginous areas because of the potential manifesta-
tion of skin atrophy and/or other side-effects [21]. The long-
term use of oral corticosteroids may also lead to adverse
effects.
A possible therapeutic option in long-standing disease is the
immunomodulators, that is, cyclosporine and tacrolimus [22].
Oral cyclosporine has been reported to be effective for AD,
but the cost of treatment and the range of potential long-term
side-effects may be even more limiting.
In view of the much more favourable relation between
therapeutic and adverse effects, the topical use of tacrolimus
will probably increase over the next several years. This drug
may represent an alternative to glucocorticoids in the
treatment of chronic inﬂammatory skin diseases, especially
for patients who have long-standing AD [23–26] and
extensive body surface area involvement, or facial lesions.
Both case reports and large, multi-centre, randomized,
controlled, double-blind clinical trials have shown the efﬁcacy
and safety of tacrolimus. A lack of epidermal atrophy and
striae distensae, both potential side-effects of topical gluco-
corticoid therapy, has been demonstrated for tacrolimus [26].
The results of our comparative study demonstrate that
tacrolimus ointment given twice daily and cyclosporine
administered orally once daily are effective on SCORAD,
on daily symptoms and on anti-H1 rescue. When we
compared tacrolimus and cyclosporine there was a faster
onset of action in the group treated with tacrolimus. In
addition, tacrolimus provided better symptoms control than
cyclosporine. This superior efﬁcacy is reﬂected in the overall
SCORED (AUC0–42) and also in the symptom score reported
during the ﬁrst 14 days after the beginning of the treatment.
At the dose used in the study, cyclosporine presented the
same safety of tacrolimus.
However, these data support the preferential use of topical
tacrolimus in AD, because cyclosporine has potential side-
effects. No data suggest clinically relevant long-term side-
effects using tacrolimus. Nevertheless, the risk of these
potential side-effects such as increased carcinogenesis and
especially photocarcinogenesis should be monitored carefully.
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